Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,301.40 +54.72 (+1.04%) Dow
39,843.50 +285.39 (+0.72%) Nasdaq
16,731.55 +220.37 (+1.33%) Bitcoin USD
65,591.98 +4,149.99 (+6.75%) CMC Crypto 200
1,381.32 +113.37 (+8.94%)
AstraZeneca PLC (AZNCF)
| Previous close | 152.88 |
| Open | 153.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 153.00 - 153.00 |
| 52-week range | 118.16 - 159.12 |
| Volume | |
| Avg. volume | 3,596 |
| Market cap | 240.365B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 37.78 |
| EPS (TTM) | 4.05 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 2.86 (1.87%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Reuters
PRESS DIGEST-British Business - May 14
The following are the top stories on the business pages of British newspapers. - Anglo American rejected a raised takeover offer of 34 billion pounds ($42.67 billion) from BHP Group on Monday, saying the world's largest listed miner "continues to significantly undervalue" the company. - JPMorgan Chase has pledged a further 40 million pounds ($50.22 million) in philanthropic investments in the UK over five years in a sign of its increasing focus on Britain.
The TelegraphUK pharma giants pledge £430m investment in France after Macron charm offensive
Britain’s two biggest pharmaceutical companies have pledged £430m of investment in France after a charm offensive by Emmanuel Macron.
ZacksBristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
